Participated · Seed · Mar 2025

Manifest is building a financial protocol that brings U.S. residential home-equity private-equity investments on-chain, letting anyone buy exposure in under 30 seconds. Its flagship product, $USH, is a token backed by Home Equity Investments (HEIs) that offers private-equity-style exposure to owner-occupied U.S. housing with the liquidity, composability and transparency of stablecoins. Capital is deployed swiftly, enabling property purchases at roughly 50% discounts to fair-market home values while every position is recorded on-chain for real-time auditability. The company targets the $35 trillion U.S. home-equity market and allows tokens to be borrowed, leveraged, or integrated across DeFi protocols, promising perpetual tax deferral and lower fees versus traditional real-estate funds. Founded by Nathaniel Sokoll-Ward (previously built and exited mortgage platform Roostify) and Robert V. Lee, Manifest graduated from crypto accelerators CV and Alliance. With its new funding, the team plans to launch $USH publicly, cement DeFi integrations, and craft additional real-world-asset financial instruments. No revenue or user counts were disclosed, but the firm positions itself as the first to make U.S. private-equity real estate globally investable at blockchain speed.

Participated · Seed · Dec 2024

MoldCo operates the first clinician-led digital health service focused on making mold detox a routine component of preventative care. Through its telehealth platform, patients can obtain symptom screening, advanced biomarker lab tests starting at $99, virtual consultations with certified mold-toxicity specialists, and prescription therapies shipped directly to their homes. Typical treatment plans cost $150–$300 per month, positioning MoldCo as a far cheaper alternative to fragmented, in-person options that can run into the tens of thousands of dollars. The company is already offering lab testing in 46 states and clinical care in select states such as Florida, Massachusetts, Michigan, Ohio, and Texas, with nationwide coverage targeted for 2026. Near-term priorities include expanding its specialist network, enhancing proprietary care technology, scaling patient onboarding, and launching clinical research collaborations to raise physician and public awareness. Backed by leading physicians, researchers, and tech VCs, MoldCo has raised $11 million to date to accelerate these initiatives.

Participated · Equity · Feb 2024

Blueprint Finance develops institutional on-chain finance infrastructure and is the core developer of Concrete, a modular full-stack vault platform. Concrete provides automated execution, accounting, risk controls, and quantitative strategy tooling to enable institutions, protocols, asset issuers, and allocators to build and operate vaults. Blueprint is expanding the Concrete ecosystem with new on-chain financial primitives such as AssetCX and concUSD. The company emphasizes bringing institutional controls—auditable accounting, operational permissions, scalable execution, and transparent risk controls—to on-chain capital allocation. Blueprint recently completed a strategic funding round to scale Concrete and to deepen partnerships across liquidity, custody, execution, and distribution. The company communicates its intent to position Concrete as the infrastructure layer for the next generation of on-chain asset management.

Participated · Seed · Jul 2022

Replay develops genomic medicine platforms, led by uCell™, an off-the-shelf hypoimmunogenic technology for making allogeneic donor-derived primary cells and iPSCs immune silent. Its toolkit also includes a high-payload HSV delivery platform (synHSV™) and a proprietary genome writing platform. Replay says uCell™ can reduce cost-of-goods, improve product volume and consistency, enable extensive genome engineering, and broaden access to cell therapies across cancer, infectious diseases, neurodegenerative diseases, and regenerative medicine. The company operates a hub-and-spoke business model that separates technology development at Replay from therapeutic development in product companies and plans to progress uCell™ through therapeutic-area-focused product companies. Replay received non-dilutive support—a $1.56 million grant from the Bill & Melinda Gates Foundation—to accelerate uCell™ development, and previously raised $55 million in seed financing in July 2022. The company is headquartered in San Diego, California and London, UK, and is led by a team of academics, entrepreneurs, and industry experts. Replay develops genome writing and delivery technologies to enable large‑payload genetic reprogramming, assembling a toolkit that includes a high‑payload HSV platform, a hypoimmunogenic platform, and a genome writing platform. The company has also established an enzyme‑writing product company that leverages its evolutionary inference machine‑learning and genome‑writing technology to optimize functionality. Replay positions these platforms to address scientific challenges limiting clinical progress and to advance genomic medicine. Its leadership team includes experienced executives and pioneers in virology and synthetic biology, and the company lists multiple academic and industry advisors and co‑founders. The article does not disclose revenue or user metrics; the only financial detail provided is the recent fundraise.

Participated · Series A · May 2022

CellX develops cultivated pork, beef, and chicken using cellular agriculture and is working across cell lines, culture media, bioprocess and end-product development. The company reports it has secured an immortalized cell line and developed a low-cost media formula, and is prioritizing the taste and texture of whole-cuts rather than mincemeat. CellX plans to scale by optimizing its platform technologies and recruiting talent to drive down unit costs. It was founded in 2020 and is an active participant in regional industry groups such as the APAC Society for Cellular Agriculture. The company positions cultivated meat as a lower-resource, lower-emission alternative to conventional animal agriculture and highlights related environmental benefits. Financially, CellX has completed a $10.6M Series A and total investment to date now exceeds $15M. CellX develops cultivated pork using structured bio-printing, scaffolding prototypes and cell-culture methods, and is also exploring cultured fish. The company debuted whole-cut cultivated pork samples at a tasting event and showcased its technology at Brinc’s Virtual Demo Day. Founded in 2020, CellX is one of roughly three Chinese firms focused on culturing meat directly from animal cells and employs a science-led team of about 25 scientists. With the new funding, the startup plans to rapidly expand its team and form scientific partnerships to accelerate R&D. CellX positions its products as solutions to China’s pork supply challenges, food security concerns and carbon-reduction commitments. The company is navigating regulatory uncertainty and consumer-acceptance hurdles even as it advances prototypes and demonstrations. CellX is a newly formed China-based cultivated meat startup focused on accelerating development and production to move cell-based products out of the laboratory. The company raised an undisclosed amount to support scale-up and product development. The article places CellX within China's nascent cultivated-meat sector, which lags markets like Israel and the U.S. due to regulatory, technical and cost challenges. Industry observers cited by the article note swift progress among some Chinese teams, with production-efficiency gains reported by the Good Food Institute for a related developer. CellX's near-term priorities, as reported, are development and production scale-up rather than immediate commercialization. No investors, valuation, revenue, or founding-year details for CellX were disclosed in the article.